Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Svanberg, R, Ostrowski, SR, Nasserinejad, K, Kersting, S, Dobber, JA, Mattson, M, Tran, HTT, Levin, M-D, Mous, R, Kater, AP & Niemann, CU 2020, 'Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib', Leukemia and Lymphoma, vol. 61, no. 14, pp. 3422-3431. https://doi.org/10.1080/10428194.2020.1811270

APA

Svanberg, R., Ostrowski, S. R., Nasserinejad, K., Kersting, S., Dobber, J. A., Mattson, M., Tran, H. T. T., Levin, M-D., Mous, R., Kater, A. P., & Niemann, C. U. (2020). Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib. Leukemia and Lymphoma, 61(14), 3422-3431. https://doi.org/10.1080/10428194.2020.1811270

CBE

MLA

Vancouver

Author

Svanberg, Rebecka ; Ostrowski, Sisse Rye ; Nasserinejad, Kazem ; Kersting, Sabina ; Dobber, Johan A ; Mattson, Mattias ; Tran, Hoa T T ; Levin, Mark-David ; Mous, Rogier ; Kater, Arnon P ; Niemann, Carsten U. / Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib. In: Leukemia and Lymphoma. 2020 ; Vol. 61, No. 14. pp. 3422-3431.

Bibtex

@article{84aec0ac7f86409f9ca00d052a30eae5,
title = "Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib",
abstract = "Bleeding is a common adverse event following ibrutinib monotherapy. However, it remains unclear how hemostasis is affected by venetoclax in combination with ibrutinib. Here we investigated hemostasis in patients with chronic lymphocytic leukemia (CLL) at baseline, during ibrutinib monotherapy, and during venetoclax and ibrutinib combination therapy or venetoclax monotherapy. Primary hemostasis, assessed by Multiplate using adenosine diphosphate (ADP), arachidonic acid (AA), and thrombin receptor agonist peptide (TRAP-6), was impaired in all CLL patients at baseline, remained unchanged upon ibrutinib monotherapy, and improved significantly following venetoclax added to ibrutinib or as monotherapy. Secondary hemostasis assessed by thromboelastography (TEG) was normal and unchanged throughout treatment. The frequency of clinical bleeding events was the highest during ibrutinib monotherapy, in line with the demonstrated improved primary hemostasis upon addition of venetoclax, thus pointing toward a treatment option for CLL patients with increased bleeding risk.",
author = "Rebecka Svanberg and Ostrowski, {Sisse Rye} and Kazem Nasserinejad and Sabina Kersting and Dobber, {Johan A} and Mattias Mattson and Tran, {Hoa T T} and Mark-David Levin and Rogier Mous and Kater, {Arnon P} and Niemann, {Carsten U}",
year = "2020",
month = dec,
doi = "10.1080/10428194.2020.1811270",
language = "English",
volume = "61",
pages = "3422--3431",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "14",

}

RIS

TY - JOUR

T1 - Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib

AU - Svanberg, Rebecka

AU - Ostrowski, Sisse Rye

AU - Nasserinejad, Kazem

AU - Kersting, Sabina

AU - Dobber, Johan A

AU - Mattson, Mattias

AU - Tran, Hoa T T

AU - Levin, Mark-David

AU - Mous, Rogier

AU - Kater, Arnon P

AU - Niemann, Carsten U

PY - 2020/12

Y1 - 2020/12

N2 - Bleeding is a common adverse event following ibrutinib monotherapy. However, it remains unclear how hemostasis is affected by venetoclax in combination with ibrutinib. Here we investigated hemostasis in patients with chronic lymphocytic leukemia (CLL) at baseline, during ibrutinib monotherapy, and during venetoclax and ibrutinib combination therapy or venetoclax monotherapy. Primary hemostasis, assessed by Multiplate using adenosine diphosphate (ADP), arachidonic acid (AA), and thrombin receptor agonist peptide (TRAP-6), was impaired in all CLL patients at baseline, remained unchanged upon ibrutinib monotherapy, and improved significantly following venetoclax added to ibrutinib or as monotherapy. Secondary hemostasis assessed by thromboelastography (TEG) was normal and unchanged throughout treatment. The frequency of clinical bleeding events was the highest during ibrutinib monotherapy, in line with the demonstrated improved primary hemostasis upon addition of venetoclax, thus pointing toward a treatment option for CLL patients with increased bleeding risk.

AB - Bleeding is a common adverse event following ibrutinib monotherapy. However, it remains unclear how hemostasis is affected by venetoclax in combination with ibrutinib. Here we investigated hemostasis in patients with chronic lymphocytic leukemia (CLL) at baseline, during ibrutinib monotherapy, and during venetoclax and ibrutinib combination therapy or venetoclax monotherapy. Primary hemostasis, assessed by Multiplate using adenosine diphosphate (ADP), arachidonic acid (AA), and thrombin receptor agonist peptide (TRAP-6), was impaired in all CLL patients at baseline, remained unchanged upon ibrutinib monotherapy, and improved significantly following venetoclax added to ibrutinib or as monotherapy. Secondary hemostasis assessed by thromboelastography (TEG) was normal and unchanged throughout treatment. The frequency of clinical bleeding events was the highest during ibrutinib monotherapy, in line with the demonstrated improved primary hemostasis upon addition of venetoclax, thus pointing toward a treatment option for CLL patients with increased bleeding risk.

U2 - 10.1080/10428194.2020.1811270

DO - 10.1080/10428194.2020.1811270

M3 - Journal article

C2 - 32865439

VL - 61

SP - 3422

EP - 3431

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 14

ER -

ID: 61698803